Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL101 in NOTCH-mutant adenoid cystic carcinoma
NCT03691207Phase 2Completed
- Sponsor
- Ayala Pharmaceuticals, Inc.
- Start
- Dec 2018
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label trial of osugacestat in adenoid cystic carcinoma (ACC) (2 arms), sponsored by Ayala Pharmaceuticals, Inc. Primary endpoint: Overall Response Rate. Started Dec 2018; status: completed.
02
Drugs
osugacestat
03
Conditions
adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on NCT03691207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03691207.